Overview

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

Status:
Active, not recruiting

Trial end date:
2022-12-11

Target enrollment:

Participant gender:

Summary

This is a prospective single arm phase II study to evaluate potential prognostic and/or predictive biomarkers in patients with metastatic ccRCC undergoing treatment with 1st line sunitinib on a 4/2 schedule followed by axitinib on 2nd line therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Instituto do Cancer do Estado de São Paulo

Collaborator:

Pfizer

Treatments:

Axitinib
Sunitinib